{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:12:46Z","timestamp":1793232766064,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82174342"],"award-info":[{"award-number":["82174342"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NATCM\u2019s Project of High-level-Construction of Key TCM Disciplines-Beijing University of Chinese Medicie-Nephrology of traditional Chinese medicine","award":["zyyzdxk-2023260"],"award-info":[{"award-number":["zyyzdxk-2023260"]}]},{"name":"Chinese Medicine Inheritance and Innovation Talent Project-Leading Talent Support Program of National Traditional Chinese Medicine","award":["Grant No. 2018, No. 12"],"award-info":[{"award-number":["Grant No. 2018, No. 12"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetic kidney disease (DKD) represents a major global health burden, affecting 20\u201340% of diabetic patients worldwide. Metabolic reprogramming mediated by hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1) plays a central role in DKD pathogenesis, yet effective therapeutic strategies remain limited. The Modified Shen-Yan-Fang-Shuai formula (M-SYFSF), a traditional Chinese medicine formulation, has demonstrated clinical efficacy in DKD treatment, but its underlying mechanisms remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A DKD model was established using streptozotocin-induced diabetic rats following unilateral nephrectomy. Thirty rats were randomly divided into sham operation, model, and M-SYFSF treatment groups (n\u2009=\u200910\/group). M-SYFSF was administered at 11.34\u00a0g\/kg\/d for 12\u00a0weeks. Renal function, histopathology, oxidative stress markers, and metabolic parameters were assessed. Human proximal tubular epithelial cells (HK-2) were treated with advanced glycation end products under hypoxic conditions to establish an in vitro DKD model. HIF-1\u03b1 overexpression and knockdown experiments were performed to investigate molecular mechanisms. Key glycolytic enzymes, mitochondrial dynamics proteins, and bioenergetic parameters were analyzed using Western blot, immunohistochemistry, immunofluorescence, and metabolic assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      M-SYFSF treatment significantly improved renal function parameters, reducing serum creatinine (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and proteinuria (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) while ameliorating characteristic DKD histopathological changes. M-SYFSF effectively suppressed HIF-1\u03b1 expression and nuclear translocation, accompanied by consistent downregulation of key glycolytic enzymes including hexokinase 2, lactate dehydrogenase, and pyruvate dehydrogenase kinase 1. Metabolic analysis revealed that M-SYFSF promoted a shift from glycolysis toward oxidative phosphorylation, restoring mitochondrial ATP production capacity. Transmission electron microscopy demonstrated that M-SYFSF preserved mitochondrial ultrastructure and improved mitochondrial respiratory chain complex activities (I, III, and IV; all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). M-SYFSF treatment enhanced mitochondrial fusion by upregulating Mfn1 and Mfn2 while suppressing fission proteins Drp1 and Fis1. HIF-1\u03b1 overexpression experiments confirmed that M-SYFSF\u2019s metabolic and mitochondrial protective effects were mediated through HIF-1\u03b1 pathway modulation. Additionally, M-SYFSF significantly reduced oxidative stress markers, including 8-OHdG and malondialdehyde levels (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), while enhancing antioxidant enzyme activities.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>M-SYFSF exerts significant nephroprotective effects in diabetic kidney disease by targeting HIF-1\u03b1-mediated metabolic reprogramming. The therapeutic mechanisms involve suppression of pathological glycolytic metabolism, restoration of mitochondrial function and dynamics, and enhancement of antioxidant capacity. These findings provide mechanistic validation for M-SYFSF as a promising multi-target therapeutic approach for diabetic kidney disease management and establish HIF-1\u03b1 as a key therapeutic target for metabolic intervention in DKD treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13020-025-01298-5","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T01:02:08Z","timestamp":1767920528000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Modified Shen-Yan-Fang-Shuai formula attenuates diabetic kidney disease progression via regulation of HIF-1\u03b1-mediated mitochondrial energy metabolism"],"prefix":"10.1186","volume":"21","author":[{"given":"Bingnan","family":"Di","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaotan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhen","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyi","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoxian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"1298_CR1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas Reports. 2023."},{"key":"1298_CR2","doi-asserted-by":"publisher","first-page":"1513008","DOI":"10.3389\/fendo.2025.1513008","volume":"16","author":"X Ma","year":"2025","unstructured":"Ma X, Liu R, Xi X, et al. Global burden of chronic kidney disease due to diabetes mellitus, 1990\u20132021, and projections to 2050. Front Endocrinol (Lausanne). 2025;16:1513008. https:\/\/doi.org\/10.3389\/fendo.2025.1513008.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"1298_CR3","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.mcna.2023.03.004","volume":"107","author":"S Gupta","year":"2023","unstructured":"Gupta S, Dominguez M, Golestaneh L. Diabetic kidney disease: an update. Med Clin North Am. 2023;107(4):689\u2013705. https:\/\/doi.org\/10.1016\/j.mcna.2023.03.004.","journal-title":"Med Clin North Am"},{"issue":"2","key":"1298_CR4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","volume":"102","author":"KR Tuttle","year":"2022","unstructured":"Tuttle KR, Agarwal R, Alpers CE, et al. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 2022;102(2):248\u201360. https:\/\/doi.org\/10.1016\/j.kint.2022.05.012.","journal-title":"Kidney Int"},{"issue":"1","key":"1298_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s13098-023-01202-x","volume":"15","author":"ET Fenta","year":"2023","unstructured":"Fenta ET, Eshetu HB, Kebede N, et al. Prevalence and predictors of chronic kidney disease among type 2 diabetic patients worldwide, systematic review and meta-analysis. Diabetol Metab Syndr. 2023;15(1):245. https:\/\/doi.org\/10.1186\/s13098-023-01202-x.","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"1298_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000526308","volume":"147","author":"P Singh","year":"2023","unstructured":"Singh P. Reprogramming of energy metabolism in kidney disease. Nephron. 2023;147(1):61\u20134. https:\/\/doi.org\/10.1159\/000526308.","journal-title":"Nephron"},{"issue":"12","key":"1298_CR7","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1016\/j.ekir.2024.09.019","volume":"9","author":"P Narongkiatikhun","year":"2024","unstructured":"Narongkiatikhun P, Choi YJ, Hampson H, et al. Unraveling diabetic kidney disease: the roles of mitochondrial dysfunction and immunometabolism. Kidney Int Rep. 2024;9(12):3386\u2013402. https:\/\/doi.org\/10.1016\/j.ekir.2024.09.019.","journal-title":"Kidney Int Rep"},{"issue":"6","key":"1298_CR8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41419-024-06833-0","volume":"15","author":"X Fan","year":"2024","unstructured":"Fan X, Yang M, Lang Y, et al. Mitochondrial metabolic reprogramming in diabetic kidney disease. Cell Death Dis. 2024;15(6):442. https:\/\/doi.org\/10.1038\/s41419-024-06833-0.","journal-title":"Cell Death Dis"},{"issue":"2","key":"1298_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrneph.2015.173","volume":"12","author":"MC Thomas","year":"2016","unstructured":"Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2016;12(2):73\u201381. https:\/\/doi.org\/10.1038\/nrneph.2015.173.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"1298_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1053\/j.ackd.2017.10.011","volume":"25","author":"DN Koye","year":"2018","unstructured":"Koye DN, Magliano DJ, Nelson RG, et al. The global epidemiology of diabetes and kidney disease. Adv Chronic Kidney Dis. 2018;25(2):121\u201332. https:\/\/doi.org\/10.1053\/j.ackd.2017.10.011.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"5","key":"1298_CR11","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/MNH.0000000000000341","volume":"26","author":"P Persson","year":"2017","unstructured":"Persson P, Palm F. Hypoxia-inducible factor activation in diabetic kidney disease. Curr Opin Nephrol Hypertens. 2017;26(5):345\u201350. https:\/\/doi.org\/10.1097\/MNH.0000000000000341.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1","key":"1298_CR12","doi-asserted-by":"publisher","first-page":"14754","DOI":"10.1038\/s41598-019-51343-1","volume":"9","author":"R Bessho","year":"2019","unstructured":"Bessho R, Takiyama Y, Takiyama T, et al. Hypoxia-inducible factor-1\u03b1 is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy. Sci Rep. 2019;9(1):14754. https:\/\/doi.org\/10.1038\/s41598-019-51343-1.","journal-title":"Sci Rep"},{"issue":"3","key":"1298_CR13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/ki.2013.130","volume":"84","author":"K Matoba","year":"2013","unstructured":"Matoba K, Kawanami D, Okada R, et al. Rho-kinase inhibition prevents the progression of diabetic nephropathy by downregulating hypoxia-inducible factor 1\u03b1. Kidney Int. 2013;84(3):545\u201354. https:\/\/doi.org\/10.1038\/ki.2013.130.","journal-title":"Kidney Int"},{"issue":"2","key":"1298_CR14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1053\/j.ajkd.2020.04.016","volume":"77","author":"M Packer","year":"2021","unstructured":"Packer M. Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics. Am J Kidney Dis. 2021;77(2):280\u20136. https:\/\/doi.org\/10.1053\/j.ajkd.2020.04.016.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"1298_CR15","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1111\/bph.12503","volume":"171","author":"GC Higgins","year":"2014","unstructured":"Higgins GC, Coughlan MT. Mitochondrial dysfunction and mitophagy: the beginning and end to diabetic nephropathy? Br J Pharmacol. 2014;171(8):1917\u201342. https:\/\/doi.org\/10.1111\/bph.12503.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"1298_CR16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2337\/db14-0874","volume":"64","author":"K Sharma","year":"2015","unstructured":"Sharma K. Mitochondrial hormesis and diabetic complications. Diabetes. 2015;64(3):663\u201372. https:\/\/doi.org\/10.2337\/db14-0874.","journal-title":"Diabetes"},{"key":"1298_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.970601","volume":"13","author":"M Wang","year":"2022","unstructured":"Wang M, Pang Y, Guo Y, et al. Metabolic reprogramming: a novel therapeutic target in diabetic kidney disease. Front Pharmacol. 2022;13:970601. https:\/\/doi.org\/10.3389\/fphar.2022.970601.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1298_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nrneph.2018.9","volume":"14","author":"JM Forbes","year":"2018","unstructured":"Forbes JM, Thorburn DR. Mitochondrial dysfunction in diabetic kidney disease. Nat Rev Nephrol. 2018;14(5):291\u2013312. https:\/\/doi.org\/10.1038\/nrneph.2018.9.","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"1298_CR19","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ebiom.2015.04.002","volume":"2","author":"A Czajka","year":"2015","unstructured":"Czajka A, Ajaz S, Gnudi L, et al. Altered mitochondrial function, mitochondrial DNA and reduced metabolic flexibility in patients with diabetic nephropathy. EBioMedicine. 2015;2(6):499\u2013512. https:\/\/doi.org\/10.1016\/j.ebiom.2015.04.002.","journal-title":"EBioMedicine"},{"key":"1298_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.118179","volume":"330","author":"XX Gong","year":"2024","unstructured":"Gong XX, Cao LH, Ni HX, et al. Chinese herbal medicine for the treatment of diabetic nephropathy: from clinical evidence to potential mechanisms. J Ethnopharmacol. 2024;330:118179. https:\/\/doi.org\/10.1016\/j.jep.2024.118179.","journal-title":"J Ethnopharmacol"},{"key":"1298_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1324782","volume":"15","author":"Y Gao","year":"2024","unstructured":"Gao Y, Li Z, Wang Y, et al. Analysis of clinical evidence on traditional Chinese medicine for the treatment of diabetic nephropathy: a comprehensive review with evidence mapping. Front Endocrinol (Lausanne). 2024;15:1324782. https:\/\/doi.org\/10.3389\/fendo.2024.1324782.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1298_CR22","doi-asserted-by":"publisher","first-page":"1327030","DOI":"10.3389\/fphar.2024.1327030","volume":"15","author":"S Zheng","year":"2024","unstructured":"Zheng S, Xu Y, Zhang Y, et al. Efficacy and safety of traditional Chinese medicine decoction as an adjuvant treatment for diabetic nephropathy: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2024;15:1327030. https:\/\/doi.org\/10.3389\/fphar.2024.1327030.","journal-title":"Front Pharmacol"},{"key":"1298_CR23","doi-asserted-by":"publisher","first-page":"5749857","DOI":"10.1142\/S0192415X22500744","volume":"2016","author":"GD Sun","year":"2016","unstructured":"Sun GD, Li CY, Cui WP, et al. Review of herbal traditional Chinese medicine for the treatment of diabetic nephropathy. J Diabetes Res. 2016;2016:5749857. https:\/\/doi.org\/10.1142\/S0192415X22500744.","journal-title":"J Diabetes Res"},{"issue":"9","key":"1298_CR24","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1016\/j.apsb.2020.12.020","volume":"11","author":"G Tang","year":"2021","unstructured":"Tang G, Li S, Zhang C, et al. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management. Acta Pharm Sin B. 2021;11(9):2749\u201367. https:\/\/doi.org\/10.1016\/j.apsb.2020.12.020.","journal-title":"Acta Pharm Sin B"},{"issue":"7","key":"1298_CR25","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1142\/S0192415X22500744","volume":"50","author":"XJ Liu","year":"2022","unstructured":"Liu XJ, Hu XK, Yang H, et al. A review of traditional Chinese medicine on treatment of diabetic nephropathy and the involved mechanisms. Am J Chin Med. 2022;50(7):1739\u201379. https:\/\/doi.org\/10.1142\/S0192415X22500744.","journal-title":"Am J Chin Med"},{"issue":"1","key":"1298_CR26","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1080\/13880209.2023.2241521","volume":"61","author":"B Yu","year":"2023","unstructured":"Yu B, Zhou M, Dong Z, et al. Integrating network pharmacology and experimental validation to decipher the mechanism of the Chinese herbal prescription modified Shen-Yan-Fang-Shuai formula in treating diabetic nephropathy. Pharm Biol. 2023;61(1):1222\u201333. https:\/\/doi.org\/10.1080\/13880209.2023.2241521.","journal-title":"Pharm Biol"},{"issue":"11","key":"1298_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12909","volume":"53","author":"N Jiang","year":"2020","unstructured":"Jiang N, Zhao H, Han Y, et al. HIF-1\u03b1 ameliorates tubular injury in diabetic nephropathy via HO-1-mediated control of mitochondrial dynamics. Cell Prolif. 2020;53(11):e12909. https:\/\/doi.org\/10.1111\/cpr.12909.","journal-title":"Cell Prolif"},{"key":"1298_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.117863","author":"Qiyan Zheng","year":"2024","unstructured":"Zheng Qiyan, Zhang X, Guo J, et al. JinChan YiShen TongLuo formula ameliorate mitochondrial dysfunction and apoptosis in diabetic nephropathy through the HIF-1\u03b1-PINK1-Parkin pathway. J Ethnopharmacol. 2024. https:\/\/doi.org\/10.1016\/j.jep.2024.117863.","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"1298_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12902-017-0200-8","volume":"17","author":"R Bohuslavova","year":"2017","unstructured":"Bohuslavova R, Cerychova R, Nepomucka K, et al. Renal injury is accelerated by global hypoxia-inducible factor 1 alpha deficiency in a mouse model of STZ-induced diabetes. BMC Endocr Disord. 2017;17(1):48. https:\/\/doi.org\/10.1186\/s12902-017-0200-8.","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"1298_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41581-023-00775-0","volume":"20","author":"S Kishi","year":"2024","unstructured":"Kishi S, Nagasu H, Kidokoro K, et al. Oxidative stress and the role of redox signalling in chronic kidney disease. Nat Rev Nephrol. 2024;20(2):101\u201319. https:\/\/doi.org\/10.1038\/s41581-023-00775-0.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"1298_CR31","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/jcmm.17116","volume":"26","author":"P Narongkiatikhun","year":"2022","unstructured":"Narongkiatikhun P, Chattipakorn SC, Chattipakorn N. Mitochondrial dynamics and diabetic kidney disease: missing pieces for the puzzle of therapeutic approaches. J Cell Mol Med. 2022;26(2):249\u201373. https:\/\/doi.org\/10.1111\/jcmm.17116.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"1298_CR32","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.tips.2022.11.004","volume":"44","author":"E Zacharioudakis","year":"2023","unstructured":"Zacharioudakis E, Gavathiotis E. Mitochondrial dynamics proteins as emerging drug targets. Trends Pharmacol Sci. 2023;44(2):112\u201327. https:\/\/doi.org\/10.1016\/j.tips.2022.11.004.","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"1298_CR33","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.050471","volume":"17","author":"JY Zhu","year":"2024","unstructured":"Zhu JY, van de Leemput J, Han Z. Promoting mitochondrial dynamics by inhibiting the PINK1-PRKN pathway to relieve diabetic nephropathy. Dis Model Mech. 2024;17(4):dmm050471. https:\/\/doi.org\/10.1242\/dmm.050471.","journal-title":"Dis Model Mech"},{"issue":"1","key":"1298_CR34","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2022.2146512","volume":"45","author":"X Ma","year":"2023","unstructured":"Ma X, Ma J, Leng T, et al. Advances in oxidative stress in pathogenesis of diabetic kidney disease and efficacy of TCM intervention. Ren Fail. 2023;45(1):2146512. https:\/\/doi.org\/10.1080\/0886022X.2022.2146512.","journal-title":"Ren Fail"},{"issue":"11","key":"1298_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11112183","volume":"11","author":"C Iacobini","year":"2022","unstructured":"Iacobini C, Vitale M, Haxhi J, et al. Mutual regulation between redox and hypoxia-inducible factors in cardiovascular and renal complications of diabetes. Antioxidants (Basel). 2022;11(11):2183. https:\/\/doi.org\/10.3390\/antiox11112183.","journal-title":"Antioxidants (Basel)"},{"issue":"11","key":"1298_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103765","volume":"28","author":"S Saxena","year":"2023","unstructured":"Saxena S, Dagar N, Shelke V, et al. Metabolic reprogramming: unveiling the therapeutic potential of targeted therapies against kidney disease. Drug Discov Today. 2023;28(11):103765. https:\/\/doi.org\/10.1016\/j.drudis.2023.103765.","journal-title":"Drug Discov Today"},{"issue":"5","key":"1298_CR37","doi-asserted-by":"publisher","DOI":"10.1172\/JCI167700","volume":"133","author":"KR Tuttle","year":"2023","unstructured":"Tuttle KR. Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors. J Clin Invest. 2023;133(5):e167700. https:\/\/doi.org\/10.1172\/JCI167700.","journal-title":"J Clin Invest"},{"issue":"1","key":"1298_CR38","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s13098-024-01531-5","volume":"16","author":"H Chen","year":"2024","unstructured":"Chen H, Su X, Li Y, Dang C, Luo Z. Identification of metabolic reprogramming-related genes as potential diagnostic biomarkers for diabetic nephropathy based on bioinformatics. Diabetol Metab Syndr. 2024;16(1):287. https:\/\/doi.org\/10.1186\/s13098-024-01531-5.","journal-title":"Diabetol Metab Syndr"},{"key":"1298_CR39","doi-asserted-by":"publisher","first-page":"1511596","DOI":"10.3389\/fneph.2024.1511596","volume":"4","author":"YA Waheed","year":"2024","unstructured":"Waheed YA, Liu J, Almayahe S, et al. The role and clinical implications of HIF-PHI daprodustat in dialysis-dependent and non-dialysis-dependent chronic kidney disease anemic patients: a general review. Front Nephrol. 2024;4:1511596. https:\/\/doi.org\/10.3389\/fneph.2024.1511596.","journal-title":"Front Nephrol"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-025-01298-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-025-01298-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-025-01298-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T01:02:09Z","timestamp":1767920529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13020-025-01298-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1298"],"URL":"https:\/\/doi.org\/10.1186\/s13020-025-01298-5","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This animal study was approved by the Ethics Committee for Experimental Animals of Dongzhimen Hospital, Beijing University of Chinese Medicine (Approval No. DZMYY24-19).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}